Want to see AVXL full AI Analyst Report?

Anavex Life Sciences (AVXL) Earnings Dates, Call Summary & Reports

1,755 Followers

Earnings Data

Report Date

Aug 11, 2026

TBA (Confirmed)

Period Ending

2026 (Q3)

Consensus EPS Forecast

-0.08

Last Year’s EPS

-0.16

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 1 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:Feb 09, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presents a cautiously optimistic tone: the company reports a strong cash position with multi-year runway, notable reductions in burn, positive clinical signals (especially in the AB-clear precision-medicine subgroup) and constructive regulatory engagement with the FDA. However, the CHMP negative opinion, a missed ADCS-ADL endpoint in the original EU submission, and remaining execution and regulatory obligations (including potential confirmatory post-approval studies) are meaningful near-term risks. Overall, positive operational and scientific developments outweigh the regulatory setbacks, but outcomes remain contingent on ongoing reexamination and further regulatory interactions.

Company Guidance

On the fiscal 2026 Q1 call (Feb 9, 2026) management gave specific operational and regulatory guidance: cash was $131.7M at Dec 31 with no debt and $7.1M of cash used in the quarter, implying a stated cash runway of more than three years at the current burn; Q1 R&D was $4.7M (down from $10.4M YoY) and G&A was $2.1M (down from $3.1M YoY), with a net loss of $5.7M or $0.06 per share; regulatory timelines include an EMA re‑examination process described as a 60+60‑day response window plus an additional ~60‑day rapporteur review (targeted in H1 2026) and a January Type C meeting with the FDA after which the company will submit the full Phase 2b/3 (Anavex 2‑73 AD‑004) data package toward next steps/NDA planning; programmatic updates include participation in the multiyear, EC‑funded Access AD initiative and a planned AD‑006 placebo‑controlled study in early AD, ongoing compassionate use in Rett and AD (Canada, UK, Australia), presentations/publications (CTAD, March 12 Johns Hopkins), pursuit of a CMA with a confirmatory post‑approval study if granted, and biomarker/genetic findings (COL24A1 prevalence estimated >70% in early AD) plus advancement of Anavex 3‑71 toward pivotal schizophrenia studies.

Strong cash position and runway

Cash of $131.7 million at Dec 31 with no debt; cash used in operating activities of $7.1 million during the quarter; company anticipates cash runway of more than three years at current burn rate.

Significant reduction in operating expenses

R&D expenses decreased to $4.7 million from $10.4 million year-over-year (≈ -54.8%); G&A decreased to $2.1 million from $3.1 million year-over-year (≈ -32.3%), driven by completion of a large blarcamesine manufacturing campaign and reduced clinical activity after completion of Anavex 3-71 Phase II.

Manageable reported loss for the quarter

Reported net loss of $5.7 million for the quarter, or $0.06 per share, consistent with lower cash utilization and expense reductions.

Positive clinical and scientific readouts presented

Late-breaking communication at CTAD affirmed identified precision-medicine patient population, reporting significant clinical and quality-of-life improvements in early Alzheimer’s disease; company cites highly clinically meaningful effect sizes (stated as ~2–3x larger than many competitors) in the AB-clear population.

Active regulatory engagement with FDA

Received feedback from an FDA Type C meeting; FDA indicated pathway options and requested submission of existing Phase 2b/3 (Anavex 2-73 AD-004) data to support next steps and potential NDA discussions.

Strategic collaborations and pipeline advancement

Participation as an industry partner in the EU-funded Access AD initiative (blarcamesine to be evaluated in a clinical prediction study); advancement plans for Anavex 3-71 toward pivotal clinical studies for schizophrenia-related disorders; multiple planned/underway publications and conference presentations on biomarkers, AB-clear population, collagen 24A1, and fragile X findings.

Anavex Life Sciences (AVXL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AVXL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 11, 2026	2026 (Q3)	-0.08 / -	-0.16	―	―	―
May 07, 2026	2026 (Q2)	-0.07 / -0.07	-0.13	46.15% (+0.06)	―	―
Feb 09, 2026	2026 (Q1)	-0.12 / -0.06	-0.14	57.14% (+0.08)	―
Nov 25, 2025	2025 (Q4)	-0.15 / -0.11	-0.14	21.43% (+0.03)	―
Aug 12, 2025	2025 (Q3)	-0.14 / -0.16	-0.14	-14.29% (-0.02)	―
May 13, 2025	2025 (Q2)	-0.15 / -0.13	-0.13	0.00% (0.00)	―
Feb 12, 2025	2025 (Q1)	-0.17 / -0.14	-0.11	-27.27% (-0.03)	―
Dec 23, 2024	2024 (Q4)	-0.16 / -0.14	-0.12	-16.67% (-0.02)	―
Aug 06, 2024	2024 (Q3)	-0.16 / -0.14	-0.14	0.00% (0.00)	―
May 09, 2024	2024 (Q2)	-0.11 / -0.13	-0.17	23.53% (+0.04)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AVXL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2026	$3.34	$3.12	-6.59%
Feb 09, 2026	$4.10	$4.35	+6.10%
Nov 25, 2025	$3.08	$3.46	+12.34%
Aug 12, 2025	$11.35	$10.78	-5.02%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.